Kapitel 55: Nierenzellkarzinom


Amendola MA, King LR, Pollack HM et al. (1990) Staging of renal carcinoma using magnetic resonance imaging at 1.5 Tesla. Cancer 66: 40–44


Amsden J, Kirchner H, Francke A et al. (1997) Results of a randomized clinical trial comparing s. c. Interleukin 2, s. c. interferon alpha 2a, and i. v. bolus 5 fluorouracil against oral tamoxifen in progressive metastatic renal cell carcinoma. Proc ASCO 16: 326a (abstract)


Cherukuri L, Johenning PW, Ram MD (1977) Systemic effects of hypernephroma. Urology 10: 93‒97
da Silva JL, Lacombe C, Bruneval P et al. (1990) Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood 75: 577‒582


Hon WC, Wilson MI, Harlos K et al. (2002) Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 417: 975–978


Land SC, Tee AR (2007) Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 282: 20534–20543


Samaan NA (1978) Paraneoplastic syndromes associated with renal carcinoma. In: Clinical conference on cancer, 23d. MD Anderson Hospital and Tumor Institute, Houston, pp 73–78


Sawczuk IS, Graham SD, Miesowicz F (1997) Randomized controlled trial of adjuvant therapy with ex vivo activated T cells in T1–3 or T4N+M0 renal cell carcinoma. Proc ASCO 16: 1163a (abstract)


Schwerdtle RF, Storkel S, Neuhaus C et al. (1996) Allelic losses at chromosomes 1p, 2p, 6p, 10p, 13q, 17p, and 21q significantly correlate with the chromophobe subtype of renal cell carcinoma. Cancer Res 56: 2927–2930


Semenza GL (2001) HIF-1, O(2), and the 3 PHDs: How animal cells signal hypoxia to the nucleus. Cell 107: 1–3


Storkel S, Eble JN, Adlakha K et al. (1997) Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80: 987–989


